Enterprise Value
0.00
Cash
6.664M
Avg Qtr Burn
N/A
Short % of Float
2.11%
Insider Ownership
9.26%
Institutional Own.
2.44%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
ZIMHI (naloxone 5mg) Details Opioid overdose | Approved Quarterly sales | |
SYMJEPI (epinephrine 0.3mg and 0.15mg) Details Anaphylaxis | Approved Quarterly sales | |
DPI-221 Details Benign prostatic hyperplasia (BPH) | Phase 1 Update | |
DPI-125 Details Opioid use disorder | Phase 1 Update | |
APC-410 (tempol) Details Acute respiratory distress syndrome, Inflammatory disease, COVID-19 | Failed Discontinued | |
APC-400 (tempol) Details Radiation Dermatitis | Failed Discontinued |